Kally­ope lands $112 mil­lion Se­ries C to ride the gut-brain ax­is for an­oth­er 3 years

Five years af­ter their launch, Kally­ope and the gut-brain ax­is are head­ed to the clin­ic — and they’re get­ting a new fire hose of cash to do so.

The biotech an­nounced a $112 mil­lion in Se­ries C fund­ing that will help bring their lead weight loss drug in­to the clin­ic lat­er this year and a drug for in­flam­ma­to­ry bow­el dis­ease not long af­ter. The syn­di­cate con­tains a long list of back­ers, most of whom had pre­vi­ous­ly in­vest­ed, in­clud­ing The Col­umn Group, Lux Cap­i­tal, Po­laris Part­ners, Eu­clid­ean Cap­i­tal, Two Sig­ma Ven­tures, Il­lu­mi­na Ven­tures, Alexan­dria Ven­ture In­vest­ments and Bill Gates. Four new in­vestors joined: Cas­din, Green­spring and two un­named in­sti­tu­tion­al in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER